BlackRock, Inc. Increases Stake in Corvus Pharmaceuticals Inc.

BlackRock, Inc. has filed a Schedule 13G with the SEC, disclosing an increased ownership in Corvus Pharmaceuticals Inc. As of the filing date, BlackRock, Inc. beneficially owns 4,015,510 shares of Corvus Pharmaceuticals Inc.'s common stock, representing a 5.4% ownership stake. This marks a significant increase in both the number of shares and the value of the investment, with a 426.37% change in value and shares. The filing indicates that BlackRock, Inc. has sole voting power over 3,960,804 shares and sole dispositive power over all 4,015,510 shares. The filing also notes that various persons have the right to receive dividends or direct the sale of the shares, but no single person's interest exceeds 5% of the total outstanding shares. The filing was signed by Spencer Fleming, Managing Director of BlackRock, Inc.